Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2025)

Xeris Biopharma Holdings' Operating Leases history spans 4 years, with the latest figure at $31.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 5.2% year-over-year to $31.5 million, compared with a TTM value of $31.5 million through Dec 2025, down 5.2%, and an annual FY2025 reading of $31.5 million, down 5.2% over the prior year.
  • Operating Leases for Q4 2025 was $31.5 million at Xeris Biopharma Holdings, down from $38.2 million in the prior quarter.
  • The five-year high for Operating Leases was $39.0 million in Q1 2024, with the low at $9.4 million in Q4 2022.
  • Average Operating Leases over 4 years is $30.9 million, with a median of $33.6 million recorded in 2024.
  • Year-over-year, Operating Leases skyrocketed 269.75% in 2023 and then fell 15.76% in 2025.
  • Tracing XERS's Operating Leases over 4 years: stood at $9.4 million in 2022, then skyrocketed by 269.75% to $34.8 million in 2023, then dropped by 4.33% to $33.3 million in 2024, then decreased by 5.2% to $31.5 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Operating Leases are $31.5 million (Q4 2025), $38.2 million (Q3 2025), and $32.4 million (Q2 2025).